Comparison

NVS-CECR2-1 European Partner

Item no. TMO-T37151-1mg
Manufacturer TargetMol
CASRN 1992047-61-6
Amount 1 mg
Quantity options 100 mg 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 0,98
Formula C27H37N5O2S
Smiles O=S(=O)(C1=NC(=CC(=N1)C2=CC=C3C(C=CN3C4CC(NC(C)(C)C4)(C)C)=C2)NC5CC5)CCC
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping Condition Cool pack
Available
Manufacturer - Targets
Apoptosis|||CDK
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
495.68
Description
NVS-CECR2-1 is a selective cat eye syndrome chromosome region candidate 2 (CECR2) inhibitor with antitumor activity and inhibits chromatin binding of CECR2 BRD. NVS-CECR2-1 is cytotoxic and can induce apoptosis.
Pathways
Cell Cycle/Checkpoint|||Apoptosis
Bioactivity
NVS-CECR2-1 is a potent inhibitor of CECR2 (cat eye syndrome chromosome region, candidate 2), a component of chromatin complexes that regulate gene expression controlling development. It binds CECR2 with high affinity (IC50 = 0.047 μM by Alpha screen, Kd = 0.80 μM by ITC). NVS-CECR2-1 demonstrates no crossreactivity in a panel of 48 bromodomains and has no major activity in kinase, protease, and receptor panels. It shows robust activity in cells by FRAP assay, due to its slow off-rate, and has no acute toxicity. See the Structural Genomics Consortium (SGC) website for more information.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close